Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop in Q1, with the Russell 2000 Growth Index (down 11.12%) trailing the Russell 2000 Value Index (down 7.74%). In the Russell 2000 Growth Index, real estate, which increased by 1.76%, outperformed all sectors both absolutely and relatively. The only other sector delivering positive returns was consumer staples, which rose by 0.67%. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its first-quarter 2025 investor letter, Carillon Eagle Small Cap Growth Fund highlighted stocks such as Protagonist Therapeutics, Inc. (NASDAQ:PTGX). Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company. The one-month return of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was 2.86%, and its shares gained 50.15% of their value over the last 52 weeks. On May 23, 2025, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stock closed at $45.66 per share with a market capitalization of $2.83 billion.

Carillon Eagle Small Cap Growth Fund stated the following regarding Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in its Q1 2025 investor letter:

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a leading biotechnology company focused on developing drugs for rare and preventable diseases. The company has two key assets: rusfertide for the treatment of polycythemia vera (a type of blood cancer) and icotrokinra for the treatment of psoriasis and ulcerative colitis. During the first quarter, a major pharmaceutical company announced that icotrokinra met its primary endpoint in a phase 2 trial in patients with ulcerative colitis, achieving a clinical remission rate that is among the highest for oral therapies addressing this condition. This positive outcome contributed to the strong performance in the stock.”

Is Protagonist Therapeutics, Inc. (PTGX) the Best Cancer Stock to Invest in for Long-Term Gain?

A research scientist wearing a lab coat working with precision in a biopharmaceutical laboratory.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held Protagonist Therapeutics, Inc. (NASDAQ:PTGX) at the end of the first quarter, which was 37 in the previous quarter. While we acknowledge the potential of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.

In another article, we covered Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and shared the list of best cancer stocks to invest in for long term gains. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.